Aliskiren in Patients With Idiopathic Membranous Nephropathy

Summary

The goal of this proposal is to conduct a pilot study to access the antiproteinuric effect of aliskiren in patients with idiopathic membranous nephropathy. Patients will be treated for 3 months with aliskiren aiming to achieve the maximum tolerated dose and blood pressure (\>100 but \<125 mmHg systolic BP \>75% of the readings).

Timeline

Start

2010-11

Primary completion

2011-12

Completion

2011-12

Drugs

Indications